JPM 2026: Takeaways for Healthcare Leaders

At this year’s JPMorgan Healthcare Conference (JPM), companies were no longer rewarded simply for being innovative, AI-enabled, or fast-growing. Instead, healthcare leaders were expected to articulate how innovation survives pricing pressure, payer friction, regulatory uncertainty and public scrutiny (often all at the same time).

Here are four signals that stand out for healthcare leaders:  

1. Deals to watch: Expect deal activity in the areas of obesity and metabolic disease, oncology, inflammation, cardiovascular disease, and neuroscience, primarily through licensing and mid-sized transactions rather than large acquisitions.

2. Regulatory outlook: FDA review timelines, approval consistency and staffing stability over the next 6 to 12 months will be critical factors shaping development strategy, investment decisions and risk tolerance.

3. AI outcomes: AI adoption alone will no longer be sufficient. Companies need to demonstrate how AI accelerates development and reduces costs.

4. Global competition: China’s growing role in biopharma and changes in U.S. research funding and manufacturing will increasingly influence long-term strategy and competitive positioning.

Themes that Defined JPM 2026

Dealmaking is Expected Throughout the Year

JPM was quieter than usual in terms of deal announcements, but that was not an indication of a slow year or rocky terrain.  

• The lack of splashy deals was seen as a timing issue – not a signal of reduced M&A activity.  

• Executives were clear that M&A activity is expected to increase in the second half of 2026 and beyond, and large pharma companies have money to spend and are actively looking.  

• With many patent expirations over the next five years, moves are unavoidable.  

AI is Still Everywhere – But It’s Also Expected

AI was referred throughout the conference, but it was no longer a headline topic.  

• For most large players, AI implementation and innovation in healthcare is assumed. It is embedded in drug discovery, clinical development, operations and regulatory work.

• AI alone is no longer a differentiator. The emphasis now is on how it is being used: for cost reduction, efficiency and improved decision-making.

• Broad claims about AI transformation are out. Measurable outcomes and impact are in.

FDA Stability – The Big Question Mark

Regulatory stability emerged as a major theme. Trust in regulatory systems has become a strategic issue, and uncertainty around approvals and standards affects innovators of all sizes.  

• Former FDA officials raised warnings about staffing challenges, leadership turnover and the loss of institutional knowledge.  

• Some industry leaders argued that the agency remains functional and is stabilizing after a period of disruption.  

• The key point is not which view proves correct, but that confidence in the regulatory system has become an ongoing topic of debate.

This discussion increasingly intersects with broader concerns about U.S. scientific leadership, research funding, and competition from China. Chinese biotech companies and partners had a significant presence at JPM, and China is increasingly viewed as a serious competitor and collaborator in early-stage research.

Key Takeaways for Healthcare Communicators

As healthcare communicators, we have an opportunity to:

• Translate complex science and strategy into clear, accessible narratives that reinforce credibility and build lasting trust.

• Help organizations explain innovation to their key stakeholders with evidence and transparency.

• Guide leaders and teams through times of change by strengthening employee engagement and promoting change resilience.